Beware denosumab discontinuation

Swiss clinicians are concerned about the possibility that a ‘severe rebound effect’ after denosumab discontinuation may underlie three cases of spontaneous vertebral fractures.

Although it is known that nine months after denosumab cessation there are increases of 40 to 50% in bone turnover markers, the authors suggest that only one study has looked at fracture risk, and that this was ‘short-term ‘ and ‘largely underpowered’.